title: Rates of fetal polydrug exposures in methadone-maintained pregnancies from a high-risk population.
abstract: Methadone maintenance treatment (MMT) is the standard of care during pregnancy for opioid-dependency, showing efficacy in improving prenatal care and reducing risk of relapse. By design, however, MMT is only intended to prevent withdrawal thus facilitating cognitive behavioural interventions. In order to maximize the benefits of MMT, it is essential that methadone is both properly prescribed and that additional addiction treatment is concurrently administered. This study aims to determine the effectiveness of MMT engagement in high-risk pregnant women in reducing polydrug use by objective laboratory examination of neonatal meconium.
  
  
  METHODS
  Over a 29-month period, the Motherisk Laboratory at the Hospital for Sick Children in Toronto analyzed meconium samples as per request by social services and hospitals for drugs of abuse.
  
  
  RESULTS
  Of the 904 meconium samples received, 273 were tested for methadone with 164 positive and 109 negative for methadone. Almost half of the methadone positive samples (46.34%) were also positive for at least one other opioid compound, which did not differ statistically from the methadone-negative control samples (46.79%; Chi square test, p=0.94). No differences were found between the methadone positive and negative groups in rates of concurrent amphetamines, cocaine, cannabis, and alcohol use indicating a similar risk of polydrug use between pregnant women taking or not taking methadone in this population.
  
  
  CONCLUSIONS
  The high rates of additional opioid and other drug use in the MMT group, suggest that MMT is failing this population of patients. It is possible that methadone doses during pregnancy are not appropriately adjusted for changes in pharmacokinetic parameters (e.g. blood volume, renal function) during the second and third trimesters. This may result in sub-therapeutic dosing creating withdrawal symptoms leading to additional substance use. Alternatively, these results may be demonstrating a substantial lack in delivery of addiction support services in this vulnerable population.
authors: Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada ; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
authors: Kaitlyn
authors: K
authors: Delano
authors: Joey
authors: J
authors: Gareri
authors: Gideon
authors: G
authors: Koren
mesh_terms: D000328:Adult; D003042:Cocaine / Q000032:analysis; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008470:Meconium / Q000737:chemistry* / Q000378:metabolism*; D008691:Methadone / Q000009:adverse effects / Q000032:analysis*; D058850:Opiate Substitution Treatment / Q000009:adverse effects*; D011247:Pregnancy
chemical_list: D003042:Cocaine; D008691:Methadone